TechnoGenesys

We have identified a new class of class of small molecule kinase inhibitor (R)-9b, which has emerged a major therapeutic solution for prostate cancer

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location St. Louis, MO, USA
  • Currency USD
  • Founded July 2011
  • Employees 1
  • Incorporation Type C-corp
  • Website technogenesys.com

Company Summary

We have identified a new class of class of inhibitor (R)-9b, which has immune modulatory activity. It has emerged to be a major therapeutic solution for prostate cancer patients those who have developed resistance to FDA-approved therapies, enzalutamide and abiraterone.

We have an investment group that is interested in investing with us and putting together a syndicate.

Our aim is to file IND by 2020, followed by clinical trials.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free